Structure Therapeutics In... (GPCR)

NASDAQ: GPCR · Real-Time Price · USD

27.31

0.31 (1.15%)

At close: May 01, 2025, 3:59 PM

27.10

-0.77%

After-hours: May 01, 2025, 05:02 PM EDT

1.15% (1D)

Bid	26.05
Market Cap	521.5M
Revenue (ttm)	n/a
Net Income (ttm)	-122.53M
EPS (ttm)	-2.34
PE Ratio (ttm)	-11.67
Forward PE	-12.66
Analyst	Buy

Ask	28.11
Volume	612,001
Avg. Volume (20D)	972,632
Open	27.20
Previous Close	27.00
Day's Range	26.16 - 27.68
52-Week Range	13.22 - 62.74
Beta	-1.46

About GPCR

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral sma...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Feb 3, 2023

Employees 163

Stock Exchange NASDAQ

Ticker Symbol GPCR

Website https://structuretx.com

Full Company Profile

Analyst Forecast

According to 9 analyst ratings, the average rating for GPCR stock is "Buy." The 12-month stock price forecast is $83.5, which is an increase of 205.75% from the latest price.

Stock Forecasts

Why Price Moved

7 months ago

+1.03%

Structure Therapeutics shares are trading higher a... Unlock content with Pro Subscription

9 months ago

-1.15%

Shares of weight loss stocks are trading lower, possibly on continued weakness following recent weight loss data from Roche, which could cause competition concerns for companies in the space.

News

2 weeks ago · zacks.com

NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback

Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.

2 weeks ago · benzinga.com

What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?

Viking Therapeutics, Inc. VKTX, Eli Lilly And Co LLY and Novo Nordisk A/S NVO stocks are trading higher on Monday.

1 month ago · youtube.com

Structure Therapeutics CEO on latest GLP-1 developments

Ray Stevens, Structure Therapeutics CEO, joins 'Fast Money' to talk advancements in weight loss drugs and the development of a GLP-1 pill.

1 month ago · seekingalpha.com

Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate

Structure Therapeutics' stock has declined over 40% since last year, but its differentiated technology platform and promising drug pipeline still support a "Buy" rating. Structure's lead candidate, al...

2 months ago · fool.com

Why Structure Therapeutics Stock Was Stumbling This Week

The past few days haven't been kind to most stocks in the white-hot obesity drugs space. One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics (GPCR 0.16%), was a vi...